Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine
Comments expressed during tour of South African clinical trial site where Emergent’s TB vaccine candidate is expected to complete enrollment in April for its Phase IIb efficacy study
ROCKVILLE, Md., Feb 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that a joint delegation of Members of the European Parliament (MEPs) and [...]
In: Chief Executive Officer, Clinical trial, Emergent Bioslutions, Fuad El-Hibri, Research and development · Tagged with: Clinical trial, European Parliament, South Africa, TB Vaccine, Tuberculosis, University of Oxford, Vaccination
Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia
ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]
In: Chief Executive Officer, El-Hibri, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Leukemia, Leukemia & Lymphoma Society · Tagged with: American Society of Hematology, Bendamustine, Clinical trial, Emergent Biosolutions Inc, Leukemia, Leukemia & Lymphoma Society, Lymphocyte
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. government
Emergent BioSolutions moves forward with typhoid vaccine
Emergent BioSolutions is on the path to finding gold with its typhoid vaccine following positive results in a Phase II trial.
The Maryland-based biopharmaceutical company is developing a single-dose oral drinkable typhoid vaccine aimed to take on Crucell’s three to four dose oral formulation and Sanofi’s injectable formulation. The global travellers market was worth $130m (€92m) [...]
In: Chief Executive Officer, Clinical trial, Emergent Bioslutions, Fuad, Fuad El-Hibri, United States · Tagged with: Clinical trial, Conditions and Diseases, Crucell, Health, Immune system, Infectious disease, Sanofi-Aventis, Vaccination
EMERGENT BIOSOLUTIONS ANNOUNCES DR. STEPHEN LOCKHART JOINS COMPANY TO LEAD COMMERCIAL PRODUCT DEVELOPMENT SUBSIDIARY
Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company’s Commercial Product Portfolio
ROCKVILLE, MD, October 18, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today that Dr. Stephen Lockhart has been appointed President, Emergent Product Development UK. Dr. Lockhart will be based at the company’s office located in Wokingham, England, and his responsibilities will include providing [...]
In: Uncategorized · Tagged with: Biotechnology and Pharmaceuticals, Business, Cambridge University, Clinical trial, Pharmaceuticals, Private Securities Litigation Reform Act, Royal College of Physicians, US Food and Drug Administration
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
In: Uncategorized · Tagged with: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
In: Uncategorized · Tagged with: Clinical trial, Fort Detrick, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government, VaxGen